| Genomic hallmarks of localized, non-indolent prostate cancer M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, ... Nature 541 (7637), 359-364, 2017 | 591 | 2017 |
| Spatial genomic heterogeneity within localized, multifocal prostate cancer PC Boutros, M Fraser, NJ Harding, R De Borja, D Trudel, E Lalonde, ... Nature genetics 47 (7), 736-745, 2015 | 521 | 2015 |
| Molecular landmarks of tumor hypoxia across cancer types V Bhandari, C Hoey, LY Liu, E Lalonde, J Ray, J Livingstone, R Lesurf, ... Nature genetics 51 (2), 308-318, 2019 | 520 | 2019 |
| Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue CS Cooper, R Eeles, DC Wedge, P Van Loo, G Gundem, LB Alexandrov, ... Nature genetics 47 (4), 367-372, 2015 | 471 | 2015 |
| Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study E Lalonde, AS Ishkanian, J Sykes, M Fraser, H Ross-Adams, N Erho, ... The lancet oncology 15 (13), 1521-1532, 2014 | 376 | 2014 |
| Widespread and functional RNA circularization in localized prostate cancer S Chen, V Huang, X Xu, J Livingstone, F Soares, J Jeon, Y Zeng, JT Hua, ... Cell 176 (4), 831-843. e22, 2019 | 344 | 2019 |
| Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway X Yang, M Fraser, UM Moll, A Basak, BK Tsang Cancer research 66 (6), 3126-3136, 2006 | 309 | 2006 |
| p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells M Fraser, BM Leung, X Yan, HC Dan, JQ Cheng, BK Tsang Cancer research 63 (21), 7081-7088, 2003 | 255 | 2003 |
| Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression S Chen, G Zhu, Y Yang, F Wang, YT Xiao, N Zhang, X Bian, Y Zhu, Y Yu, ... Nature cell biology 23 (1), 87-98, 2021 | 235 | 2021 |
| Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets DC Wedge, G Gundem, T Mitchell, DJ Woodcock, I Martincorena, M Ghori, ... Nature genetics 50 (5), 682-692, 2018 | 232 | 2018 |
| Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories RA Taylor, M Fraser, J Livingstone, SMG Espiritu, H Thorne, V Huang, ... Nature communications 8 (1), 13671, 2017 | 228 | 2017 |
| The evolutionary landscape of localized prostate cancers drives clinical aggression SMG Espiritu, LY Liu, Y Rubanova, V Bhandari, EM Holgersen, LM Szyca, ... Cell 173 (4), 1003-1013. e15, 2018 | 227 | 2018 |
| Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway JQ Cheng, X Jiang, M Fraser, M Li, HC Dan, M Sun, BK Tsang Drug resistance updates 5 (3-4), 131-146, 2002 | 225 | 2002 |
| Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer H Guo, M Ahmed, F Zhang, CQ Yao, SD Li, Y Liang, J Hua, F Soares, ... Nature genetics 48 (10), 1142-1150, 2016 | 223 | 2016 |
| Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function M Fraser, T Bai, BK Tsang International journal of cancer 122 (3), 534-546, 2008 | 219 | 2008 |
| Chemoresistance in human ovarian cancer: the role of apoptotic regulators M Fraser, B Leung, A Jahani-Asl, X Yan, WE Thompson, BK Tsang Reproductive biology and endocrinology 1, 1-13, 2003 | 219 | 2003 |
| The proteogenomic landscape of curable prostate cancer A Sinha, V Huang, J Livingstone, J Wang, NS Fox, N Kurganovs, ... Cancer Cell 35 (3), 414-427. e6, 2019 | 192 | 2019 |
| TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer KJ Kron, A Murison, S Zhou, V Huang, TN Yamaguchi, YJ Shiah, M Fraser, ... Nature genetics 49 (9), 1336-1345, 2017 | 179 | 2017 |
| A prostate cancer “nimbosus”: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies MLK Chua, W Lo, M Pintilie, J Murgic, E Lalonde, V Bhandari, ... European urology 72 (5), 665-674, 2017 | 172 | 2017 |
| PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy M Fraser, H Zhao, KR Luoto, C Lundin, C Coackley, N Chan, AM Joshua, ... Clinical Cancer Research 18 (4), 1015-1027, 2012 | 158 | 2012 |
Paul C. BoutrosUniversity of California, Los AngelesVerified email at mednet.ucla.edu
